Effect of Zilongjin Tablets on survival time of patients with advanced non-small cell lung cancer

YOU Jiafeng; YU Mingwei; SHANG Beibei; ZHANG Yi; ZHANG Jiahui; LIU Qiang; GUO Qiuxiang; WANG Xiaomin; YANG Guowang

doi:10.16025/j.1674-1307.2024.03.005

您当前的位置：

首页 >

文章列表页 >

Effect of Zilongjin Tablets on survival time of patients with advanced non-small cell lung cancer

更新时间：2024-04-30

- Effect of Zilongjin Tablets on survival time of patients with advanced non-small cell lung cancer
- Beijing Journal of Traditional Chinese Medicine Vol. 43, Issue 3, Pages: 250-255(2024)
- 作者机构：
  
  1.首都医科大学附属北京中医医院肿瘤科，北京 100010
  2.世界中医药学会联合会评价中心，北京 100101
  3.北京市天之力医药科技开发有限公司，北京 100028
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2024.03.005
  CLC：
- Published：25 March 2024，
  
  Received：30 August 2023，
扫描看全文
游佳凤，于明薇，尚贝贝，等.紫龙金片对中晚期非小细胞肺癌患者生存时间的影响［J］.北京中医药，2024，43（3）：250-255.

YOU Jiafeng,YU Mingwei,SHANG Beibei,et al.Effect of Zilongjin Tablets on survival time of patients with advanced non-small cell lung cancer[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(03):250-255.
游佳凤，于明薇，尚贝贝，等.紫龙金片对中晚期非小细胞肺癌患者生存时间的影响［J］.北京中医药，2024，43（3）：250-255. DOI： 10.16025/j.1674-1307.2024.03.005.

YOU Jiafeng,YU Mingwei,SHANG Beibei,et al.Effect of Zilongjin Tablets on survival time of patients with advanced non-small cell lung cancer[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(03):250-255. DOI： 10.16025/j.1674-1307.2024.03.005.

摘要

目的

探讨紫龙金片参与治疗对中晚期非小细胞肺癌患者生存时间的影响。

方法

采用前瞻性、观察性真实世界队列研究方法，收集首都医科大学附属北京中医医院肿瘤科中晚期肺癌的医疗健康数据及基于研究目的采集的数据构成数据库，从中调取临床分期为ⅢB~Ⅳ期患者相关资料。以是否服用紫龙金片为暴露因素，提取患者人口学、肺癌诊断、治疗、紫龙金片服用等相关信息，采用

Kaplan-Meier

法进行单因素分析，COX模型法进行多因素生存分析。

结果

最终301例患者纳入研究，其中暴露队列99例、非暴露队列202例。暴露队列经手术治疗比例高于非暴露队列（

0.05）。暴露队列预估平均生存时间为1 085.990 d［95％

（964.694，1 207.286）］，高于非暴露队列的840.074 d［95％

（748.942，931.207）］，差异有统计学意义（

=0.002）。单因素分析结果显示，患者性别、年龄、病理类型、TNM临床分期、手术治疗、紫龙金片暴露与生存时间相关（

≤0.1）。COX回归模型多因素分析结果显示，老年、肺鳞状细胞癌、较晚临床分期是死亡终点时间的独立危险因素，而女性、接受手术治疗、化学药物治疗、靶向治疗、紫龙金片治疗为独立保护因素，其中临床分期、手术治疗、紫龙金片暴露差异有统计学意义（

0.05）。

结论

基于当前数据及分析方法，紫龙金片参与治疗对于中晚期非小细胞肺癌患者的生存时间表现出较为明显的保护作用。

Abstract

Objetive To investigate the effect of Zilongjin Tablets on the survival time of patients with advanced non-small cell lung cancer.

Methods

A prospective，observational real-world study was used. The research database was composed of data proactively collected for the purpose of this study，medical and health data from Beijing Hospital of Traditional Chinese Medicine. The data of patients in the Phase ⅢB~Ⅳ clinical stage were extracted. Whether or not Taking Zilongjin tablets was considered as an exposure factor. The information including patients’ demography， lung cancer diagnosis， treatment， and administration of ZilongjinTtablets were extracted and Kaplan-Meier method was used for univariate analysis，and COX model method was used for multivariate survival analysis.

Results

A total of 301 cases were included， including 99 exposed queues and 202 unexposed queues. The proportion of surgical treatment in exposed group was higher than that in non-exposed group （

0.05）. The estimated mean survival time in the exposed cohort was 1 085.990 d［95％

（964.694，1 207.286）］， higher than that in the non-exposed cohort 840.074 d［95％

（748.942，931.207）］， the difference was statistically significant （

=0.002）. Univariate analysis showed that sex， age， pathological type， TNM clinical stage， surgical treatment and exposure to Zi Long gold tablets were related to survival time （

≤0.1）.COX survival analysis showed that older age， squamous cell carcinoma and late clinical stage were independent risk factors for terminal events， while female， surgery， chemotherapy， targeted therapy and exposure to Zilongjin Tablets were independent protective factors， among which there were statistically significant differences between clinical stage，surgery and exposure to Zilongjin Tablets （

0.05）.

Conclusion

Based on the current data and analysis methods，the treatment with Zilongjin Tablets has a relatively clear protective effect on the survival in patients with advanced non-small cell lung cancer.

关键词

中晚期非小细胞肺癌真实世界数据紫龙金片

Keywords

Advanced non-small cell lung cancerreal world dataZilongjin Tabletspost-marketing evaluation of Chinese patent medicine

references

SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022,72(1):7-33.

SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249.

ZHENG R, ZHANG S, ZENG H, et al. Cancer incidence and mortality in China, 2016[J]. Journal of the National Cancer Center, 2022,2(1):1-9.

SIEGEL RL, MILLER KD, WAGLE NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023,73(1):17-48.

石远凯,孙燕,于金明,等.中国晚期原发性肺癌诊治专家共识(2016年版)[J].中国肺癌杂志,2016,19(1):1-15.

于明薇, 刘强, 吴万垠,等. 基于多中心真实世界数据的紫龙金片辅助治疗肺癌患者生存分析[J]. 中草药,2022,53(12):3730-3739.

中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志,2018,40(12):935-964.

郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社,2002:216-383.

林丽珠, 王思愚, 黄学武. 肺癌中西医结合诊疗专家共识[J]. 中医肿瘤学杂志,2021,3(6):1-17.

SU XL, WANG JW, CHE H, et al. Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer[J]. Chin Med J (Engl), 2020,133(24):2987-2997.

桂越蓉,王学谦,李玉潇,等.肺癌中医证候要素及症状分布情况研究[J].中医肿瘤学杂志,2021,3(4):12-16.

郭雯, 冯贞贞, 王露,等. 基于文献的肺癌常见中医证候研究[J]. 中医杂志,2021,62(16):1447-1454.

刘文瑞, 冯贞贞, 李建生. 基于文献的不同分期非小细胞肺癌患者中医证候、证素分布规律研究[J]. 中医杂志,2021,62(18):1635-1639.

王学林, 王亮, 王鹏,等. 杨明会从痰论治原发性肺癌经验[J]. 北京中医药,2022,41(8):867-869.

刘槟, 燕晓茹, 何杰,等. 活血化痰法防治肺癌EGFR-TKI靶向治疗耐药机制探讨[J]. 北京中医药,2022,41(2):164-167.

游佳凤, 于明薇, 杨国旺. 紫龙金片临床应用及相关机理研究进展[J]. 世界科学技术-中医药现代化,2023,25(3):871-876.

宋从宽,李东航,卢子龙,等.基于网络药理学和分子对接探究紫龙金片主要成分治疗非小细胞肺癌的作用机制[J].武汉大学学报(医学版),2023,44(9):1078-1085.

赵林林,王艳亭,孔凡铭,等.7种常用口服中成药辅助治疗晚期非小细胞肺癌患者的回顾性研究[J].中草药,2022,53(16):5119-5127.

石翔,王朝栋,李珊,等.PET/CT诊断肺腺癌与肺鳞状细胞癌的价值观察[J].中国CT和MRI杂志,2022,20(9):47-49.

ISLAMI F, CHEN W, YU XQ, et al. Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013[J]. Ann Oncol, 2017,28(10):2567-2574.

HAMID MS, SHAMEEM R, GAFOOR K, et al. Non-small-cell lung cancer clinicopathologic features and survival outcomes in Asian Pacific Islanders residing in the United States: A SEER Analysis[J]. J Cancer Epidemiol, 2015,2015:269304.

陈伟伟, 张宁苏, 张惠子. 肺腺癌证型分布及相关因素分析[J]. 中医临床研究,2022,14(14):121-123.

龚竹,邹国荣,曹小龙,等.肺腺癌EGFR突变患者一线化疗与靶向治疗生存分析[J].海南医学,2016,27(3):367-370.

周睿, 倪静, 赵倩,等. 肿瘤负荷在上皮性卵巢癌中的研究进展[J]. 肿瘤学杂志,2022,28(10):866-871.

许博文,吴静远,李杰,等.肿瘤中成药上市后生存获益评价的探索与实践[J].中国中药杂志,2021,46(8):1980-1987.

曹俊岭, 李学林, 李春晓,等. 中成药临床应用专家共识(第一版)[J]. 中国药学杂志,2022,57(6):502-506.

王敏, 徐挺立, 顾雪婷,等. 基于疗程和用药时间优化我院中成药处方点评体系[J]. 中医药管理杂志,2022,30(11):148-150.

赵颖, 杨园园, 王耀献,等. 中药上市后临床有效性再评价技术规范(初稿)[J]. 中国中药杂志,2018,43(15):3211-3215.

柏柳安宁,夏结来,王陵,等.真实世界研究中的常见偏倚及其控制[J].中国临床药理学与治疗学,2020,25(12):1422-1428.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰